

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9315 • CHR. HANSEN / LONZA / JV

SECTION 1.2

Description of the concentration

Chr. Hansen is a global bioscience company that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. It supplies cultures, probiotics, enzymes and natural colours.

Lonza is a company active in the supply of various services from research to final product manufacturing in the pharmaceutical, health care and life science industries worldwide. It is also active in the manufacture and development of active ingredients for use in the agricultural sector and surface protection in various industries.

Lonza Ltd and Chr. Hansen Holding A/S have entered into an agreement for the establishment of a full-function 50/50 joint venture constituting a market-facing and autonomous CDMO with its own production facilities.

The JV shall exclusively engage in the activities of a CDMO for LBP-APIs for third party customers with the intent of formulating LBP-APIs into products intended to be used or registered as medicinal products to cure, treat or prevent diseases.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.